The developer of multiplex PCR technologies entered into the JV with Biodist Group to accelerate adoption of molecular diagnostic (MDx) technologies in the Latin American market that includes Mexico and other Central and South American countries.
The new company, Biodist-Seegene Diagnostics, was established with an ownership stake of 50% each. Seegene will license its proprietary MDx technologies and development know-hows to Biodist-Seegene Diagnostics. Biodist Group will provide a marketing and sales distribution network.
Seegene said its multiplex technologies enable simultaneous detection and identification of multiple pathogens or targets in a single test.
Biodist-Seegene Diagnostics aims to develop, manufacture and commercialize localized products in Mexico and expand its market presence to the fast-growing Latin American markets.
In addition to its current business in human in vitro diagnostic (IVD), Seegene is seeking to expand applicability of its technologies into markets such as agriculture and food safety testing.
Seegene said its core enabling technologies, ACP, DPO, READ, TOCE and MuDT, are the foundation for multiplex clinical molecular diagnostics (M-MoDx) tests.